Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
FAM83G (PAWS1) is a member of the FAM83 protein family distinguished by the conserved DUF1669 domain. It acts as an intracellular scaffold, modulating key signaling pathways. Originally identified as a SMAD1 interactor, it mediates non-canonical BMP signaling and is phosphorylated by type I BMP receptor kinases. FAM83G controls the expression of some BMP target genes independently of canonical SMAD4 activity, and has additional roles in Wnt/β-catenin signaling by anchoring CK1 isoforms, supporting β-catenin nuclear accumulation, and driving Wnt-dependent gene transcription. Loss-of-function mutations cause defects in actin cytoskeletal regulation and cell migration, and are associated with hereditary keratoderma and abnormal hair development in humans and animals. FAM83G is not a classical receptor, enzyme, or transporter, but is notable for its cellular regulatory roles and disease relevance. Not an enzyme, transporter, or receptor; best classified as a scaffolding/signaling cofactor protein. Experimental evidence favors a role in cytoskeletal dynamics, embryogenesis, and cutaneous biology, not as a direct drug target. Human pathogenic mutations (A34E, others) disrupt associations with CK1 and attenuate canonical Wnt signaling. FAM83G/PAWS1 is a conserved scaffolding/signaling protein that interacts with SMAD1 and CK1 isoforms to regulate non-canonical BMP and canonical Wnt signaling. It is not currently considered a direct therapeutic target, but mutations cause skin and hair pathology, providing a model for understanding related signaling networks.
Not applicable; no drugs are currently described as acting via FAM83G.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Family with sequence similarity 83 member G (FAM83G).